WebSep 23, 2024 · The tolerability and safety of CT103A cells will be assessed in an initial dose of 0.5×10^6 CAR-T cells/Kg and three subjects will be enrolled firstly. If no dose-limiting … WebDec 22, 2024 · About CT103A. Equecabtagene autoleucel (CT103A) is a BCMA chimeric antigen receptor autologous T cell injection, a lentiviral vector containing a CAR structure with a fully human scFv, CD8a hinger and transmembrane, 4-1BB co-stimulatory and CD3ζ activation domains. Based on strict selection and screening, utilizing a proprietary in …
IASO Bio Announces CT103A Granted Regenerative Medicine …
WebFeb 14, 2024 · CT103A is an innovative therapy co-developed by IASO Bio and Innovent. Previous studies indicate subjects with relapsed/refractory multiple myeloma (R/R MM) who received high-dose BCMA-targeting CAR-T cells may achieve better remission but have worse adverse events. Moreover, once the disease progresses again, the re-infusion of … puuvarasto mökille
S187: UPDATED PHASE 1/2 DATA OF SAFETY AND EFFICACY OF …
CT103A is a fully human anti-BCMA CAR engineered T cell which overcomes this big hurdle and thus induces and potentially sustains complete remissions. However, there still remain other challenges of CAR-T cells in MM, including T cell- and tumor-related challenges, including the underlying health status of the immune compartment and the immune ... WebFeb 13, 2024 · About CT103A Equecabtagene autoleucel (CT103A) is a BCMA chimeric antigen receptor autologous T cell injection, a lentiviral vector containing a CAR structure with a fully human scFv, CD8a hinger ... WebFeb 14, 2024 · Fully human anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy (CT103A) has received orphan drug designation (ODD) from the … puuvarasto.fi